Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

Rhea-AI Summary

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced it will present preclinical data at the American Academy of Neurology Annual meeting from April 2-7, 2022. This data highlights their innovative approach to inhibiting C1q in complement-mediated diseases, which includes conditions like Guillain-Barré Syndrome and Huntington’s disease. Notable presentations include the efficacy of their therapy ANX005. The company aims to advance its clinical programs, leveraging its proprietary platform aimed at combating various complement-mediated disorders.

Positive

• Presentation of preclinical data at a prominent conference, potentially increasing visibility.
• Efficacy of therapy ANX005 shown in Guillain-Barré Syndrome, supporting the advancement of clinical programs.
• Focus on a promising approach to complement-mediated diseases, which could lead to new therapies.

Negative

• None.

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology (AAN) Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022.

“Annexon was built on the hypothesis that inhibiting C1q and the early classical complement cascade right at the start could be translated into therapies that potentially provide more complete protection against a number of complement-mediated disorders,” said Ted Yednock, Ph.D., executive vice president and chief innovation officer of Annexon. “The data we are presenting at AAN support that hypothesis and the continued advancement of several of our clinical-stage programs, including those in Guillain-Barré Syndrome and Huntington’s disease. We look forward to sharing these data at the meeting and continuing to explore the potential of our pioneering approach to addressing complement-mediated diseases.”  

Oral Presentations
Title: 001. Anti-C1q Therapy ANX005 Inhibits CSF Antibody-Driven Complement Activity Elevated in Early Stage Guillain-Barré Syndrome
Session: S25: Autoimmune Neurology 2: Clinical Trials and Treatment
Date & Time: April 5, 2022, at 3:30 p.m. PT

Title: 002. Effect of Combined Intravenous Immunoglobulin and Classical Complement Inhibitor ANX005 in Guillain-Barré Syndrome
Session: S25: Autoimmune Neurology 2: Clinical Trials and Treatment
Date & Time: April 5, 2022, at 3:42 p.m. PT

Title: 3372. Inhibition of C1q Reduces Nerve Damage as Measured by Neurofilament Light Chain in the HD R6/2 Mouse Model
Session: S36: Movement Disorders: Clinical and Pathologic Characterization of Neurodegenerative Movement Disorders
Date & Time: April 7, 2022, at 1:36 p.m. PT

Poster Presentation
Title: 3302. Inhibiting C1q Improves Compound Muscle Action Potential and Reduces Neuronal Damage in the SOD1G93A Mouse Model
Session: P1: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1
Date & Time: April 2, 2022, from 8:00-9:00 a.m. PT

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

FAQ

What is Annexon's approach to treating complement-mediated diseases?

Annexon focuses on inhibiting C1q to block the classical complement pathway, aiming to provide therapies for autoimmune, neurodegenerative, and ophthalmic disorders.

When and where will Annexon present its preclinical data?

Annexon will present its preclinical data at the American Academy of Neurology Annual meeting from April 2-7, 2022, in Seattle and virtually.

What are the key presentations by Annexon at the AAN meeting?

Key presentations include data on ANX005 in Guillain-Barré Syndrome with sessions scheduled for April 5 and additional findings on nerve damage reduction in Huntington's disease on April 7.

How could Annexon's research impact the market?

Successful data presentation could enhance investor confidence and attract interest in Annexon's therapies aimed at complement-mediated diseases.